This study employed 3'-deoxy-3'-[F-18]-fluorothymidine ([F-18]FLT) microPET scanning to assess the treatment response of histone deacetylase inhibitors (HDACi), e.g., N1-hydroxy-N8-phenyloctanediamide (SAHA) and its iodinated derivative ISAHA, in a hepatoma mouse model.
The in vitro cytotoxicity of HDACi in various hepatoma cell lines was determined by MTT assay and flow cytometry. ISAHA and SAHA were used to treat HepG2 hepatoma xenograft-bearing mice. The treatment responses were characterized in terms of tumor burden, microPET imaging, and immunohistochemical staining of tumor sections.
ISAHA effectively inhibited HepG2 hepatoma cell survival and tumor growth. A significantly reduced tumor uptake during HDACi treatment was noticed in [F-18]FLT microPET imaging, which was consistent with the findings in immunohistochemical staining.
ISAHA can suppress tumor cell proliferation both in vitro and in vivo. [F-18]FLT PET is a promising modality for evaluating the in vivo therapeutic efficacy of HDACi at the early stage of treatment.
關聯:
MOLECULAR IMAGING AND BIOLOGY 卷: 17 期: 3 頁碼: 394-402
